Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

CNBC April 9, 2024
Annika Kim Constantino

Key Points

– A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial.

– The initial data suggests that Pfizer’s shot, known as Abrysvo, could help protect a far wider population from RSV.

– Pfizer said it plans to submit the data to regulatory agencies and file for an expanded approval of the shot, which is currently approved for adults ages 60 and above and expectant mothers.

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late...

Today's Sponsors

Today's Sponsor